Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 50Leukemia 15Gastrointestinal Stromal Tumors 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Chronic-Phase 8Neoplasms 5Philadelphia Chromosome 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Bone Marrow Diseases 4Blast Crisis 4Hematologic Diseases 3Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Recurrence 1Piebaldism 1Neoplastic Processes 1Neoplasms by Histologic Type 1Melanoma 1Mastocytosis, Systemic 1Leukemia, Myeloid, Accelerated Phase 1Hypereosinophilic Syndrome 1Disease Progression 1

Interventions

Imatinib Mesylate 3nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hypereosinophilic Syndrome × nilotinib × Clear all
NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Novartis

Phase 1/2 Completed
507 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡